| ［1］Meier Y,Cavallaro M,Roos M,et al．Incidence of drug-induced liver injury in medical inpatients．Eur J Clin Pharmacol，2005，61（2）：135-143．［2］刘旭东,王炳元.我国药物性肝损害2003—2008年文献调查分析.临床误诊误治,2010，23（5）：487-488.［3］Baghaei P,Tabarsi P,Chitsaz E,et al. Incidence,clinical and epidemiological risk factors,and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Am J Ther,2010,17（1）:17-22.［4］Xia YY,Hu DY,Liu FY,et al.Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study(ADACS). BMC Public Health，2010,10:267.［5］Stirnimann G,Kessebohm K,Lauterburg B. Liver injury caused by drugs:an update. Swiss Med Wkly，2010，140:w13080.［6］Singla R,Sharma SK,Mohan A,et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res，2010,132:81-86.［7］Chang KC,Leung CC. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate. Clin Infect Dis,2010,51(3):366-367.［8］Warmelink I,ten Hacken NH,van der Werf TS,et al. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. Br J Nutr,2010，105(3):1-9.［9］Kunst H,Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection:a systematic review. Int J Tuberc Lung Dis,2010，14(11):1374-1381.［10］Makhlouf HA,Helmy A,Fawzy E,et al. A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Hepatol Int,2008，2(3):353-360.［11］Fountain FF，Tolley E，Chrisman CR，et al．Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection：a 7-year evaluation from a public health tuberculosis clinic．Chest，2005，128(1)：116-123．［12］Villarino ME，Ridzon R，Weismuller PC，et al．Rifampin preventive therapy for tuberculosis infection：experience with 157 adolescents．Am J Respir Crit Care Med,1997，155(5)：1735-1738．［13］Chang KC,Leung CC,Yew WW,et al. Hepatotoxicity of pyrazinamide:cohort and case-control analyses. Am J Respir Crit Care Med,2008,177（12）:1391-1396.［14］Andrade RJ,Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother,2011,66(7):1431-1446.［15］Harshad Devarbhavi. An update on drug induced liver injury.J Clini Experim Hepato,2012,2(3):247-259.［16］Saukkonen JJ,Cohn DL,Jasmer RM,et al. An official ATS statement:hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med,2006,174(8):935-952.［17］Devarbhavi H,Dierkhising R,Kremers WK,et al. Single-center experience with drug-induced liver injury from India:causes,outcome,prognosis,and predictors of mortality. Am J Gastroenterol,2010,105(11):2396-2404.［18］肖东楼,马玙,朱莉贞.抗结核药品不良反应诊疗手册.北京:人民卫生出版社,2010:14-62.［19］Shang P,Xia Y,Liu F,et al. Incidence,clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury(ATLI)in China. PLoS One,2011,6(7):e21836.［20］Babalk A,Arda H,Bakrc N,et al. Management of and risk factors related to hepatotoxicity during tuberculosis treatment. Tuberk Toraks,2012,60(2):136-144.［21］夏愔愔,詹思延.国内抗结核药物不良反应发生率的综合分析.中华结核和呼吸杂志,2007,30(6):419-423.［22］Keshavjee S,Gelmanova IY,Shin SS,et al. Hepatotoxicity during treatment for multidrug-resistant tuberculosis:occurrence,management and outcome. Int J Tuberc Lung Dis,2012,16(5):596-603. |
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
